Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...

Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.

Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...

January is a big time for drugmakers to hike prices. This year saw higher prices for 575 medications so far, including ...

J.P. Morgan analyst Jessica Fye has maintained their bearish stance on MRNA stock, giving a Sell rating yesterday.Stay Ahead of the ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor ...

A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 10:30 AM ETCompany ParticipantsDr.

Sage Therapeutics, Inc. today announced that Chief Executive Officer Barry Greene will discuss the Company's strategic focus areas for 2025 at the 43rd Annual J.P. Morgan Healthcare Conference in San ...

This Fool has his eye on an innovative growth stock that has plunged by 80% since early 2021. But what is so special about it ...

FAYETTEVILLE, NY, UNITED STATES, January 10, 2025 /EINPresswire / -- Additional January 2025 Prescription Drug Price Changes Show Further ...

US biopharma Vertex Pharmaceuticals has entered an exclusive collaboration and license agreement with China’s Zai Lab for the ...